Microsoft has named Chad Thompson as CVP of Agent Cloud, placing a new leader over a group building technology to help businesses deploy AI agents across their organizations. In his LinkedIn post, Thompson described enterprise AI’s value in terms of measurable outcomes, including reduced costs and shorter work cycles. His appointment sits alongside leadership changes in healthcare, financial services and AI accountability, where applying the technology requires more than a working demonstration.
Three appointments show where deployment work is concentrating:
- Microsoft’s Agent Cloud is focused on helping organizations put AI agents into use.
- BECU has named Geoffrey Fonga as VP of AI transformation; he joins from DataRobot.
- Lila Bio and RevealDx are adding expertise needed to develop and commercialize AI-enabled healthcare products.
Enterprise Agents Need Platforms and Internal Ownership
Agent Cloud’s remit connects AI development to everyday business operations. The group is developing technology that lets enterprises deploy agents and use them throughout their organizations. Thompson’s stated priorities include improved decisions and work that progresses with less human prompting, alongside cost and cycle-time improvements. Those are goals for deployment, rather than reported results.
Thompson joins Microsoft from Alteryx. His background includes six years at Amazon, where he last served as general manager of Amazon Glow, as well as roles at Smartsheet, Exasol and Adobe. That experience spans several technology businesses; his new responsibility is specifically about making agents usable across an enterprise. For a business evaluating this approach, the distinction is practical. An agent that performs a task in a demonstration still needs to fit into an operating workflow. Thompson’s emphasis on measurable results suggests that buyers should evaluate whether deployment changes the work itself, rather than treating access to agents as the outcome.
At BECU, Geoffrey Fonga, VP of AI transformation, will approach adoption from inside the organization. Based in Tukwila, Wash., the credit union is not-for-profit and member-owned. Before joining from DataRobot, Fonga held leadership positions at McKinsey & Company and Wells Fargo. Fonga described a move from advising organizations and supplying their technology to being responsible for transformation within an organization. His comments identify a useful distinction for enterprise adoption: recommending an approach and carrying it through within an organization involve different responsibilities. BECU’s announcement does not identify particular member-facing applications or operational deployments, so the appointment should not be read as evidence of those outcomes.
Accountability is another part of the deploymeEdna Conway, former Cisco and Microsoft security executivety executive, has joined the advisory council at Known. Based in Bellevue, Wash., the company is developing infrastructure intended to support accountability for AI agents. Conway spent 20 years at Cisco before moving to Microsoft in 2020 as VP and chief security and risk officer for Azure infrastructure. Her appointment brings security and risk experience to a company addressing agent accountability. Prospective users will need to consider how responsibility stays clear as software takes on more work. The announcement doesn’t establish how Known’s infrastructure performs in practice.
Healthcare Appointments Connect AI Development With Clinical Use
Lila Bio’s use of AI has a specific therapeutic objective: designing new proteins for cancer treatment using targeted radiation. The Seattle biotech startup emerged from Nobel laureate David Baker’s laboratory at the University of Washington. Last year, it announced a collaboration with Eli Lilly aimed at developing treatments for solid tumors. Kimberly Ma, chief development officer, joins with 20 years of oncology drug-development experience. Her most recent leadership role was at Abdera Therapeutics. Before that, she headed clinical operations at RayzeBio, supporting its IPO and subsequent acquisition by Bristol Myers Squibb for $4.1 billion in 2024.
Her background is relevant to the distance between a promising design and a treatment developed for clinical use. AI supplies part of Lila Bio’s approach to creating proteins; oncology development expertise supports the work required to advance therapies. Neither the appointment nor the collaboration announcement establishes treatment effectiveness.
RevealDx is applying AI to a different point in healthcare: identifying lung nodules that may be cancerous. The Seattle-based company has appointed Dr. Ryan Brevard, medical director, and David Austin, VP of sales. Together, the roles address medical expertise and commercial adoption around the product.
Brevard previously advised RevealDx and assisted with obtaining FDA clearance. His experience in emergency medicine and critical care spans more than 23 years. Austin’s nearly 30 years of experience covers diagnostic imaging, radiology and commercialization of medical technology.
FDA clearance marks a concrete milestone, though on its own it doesn’t show how a product performs across every clinical setting. The appointments reflect two requirements for adoption: understanding the clinical use of a medical product and having the commercial expertise to reach users. The announcement provides no figures for diagnostic performance or customer uptake.
Cloud, Energy and Commercial Leadership Changes Broaden the Picture
Amazon has recruited Mazhar Mohammed, vice president of AWS Streaming and Messaging, after more than 33 years at Microsoft. He began there as a software design engineer working on Windows NT after completing a master’s program. His subsequent responsibilities covered messaging, mobile services and the partner experience around cloud services. Most recently, Mohammed was corporate VP for the commerce and fraud protection platform. He shared his move through LinkedIn. The new role concerns AWS Streaming and Messaging; no specific AI initiative was identified in the announcement.
Other appointments concern finance, policy, regional operations and commercialization. They help distinguish the broader technology leadership reshuffle from roles explicitly focused on AI.
| Organization | Leadership change | Responsibility or relevant background |
|---|---|---|
| Amazon | Gail Carpenter, VP and chief financial officer of Global Entertainment and Advertising | Previously CFO of Worldwide Stores Finance; has spent 11 years at Amazon. |
| Amazon | Andre Woodson Jr., manager of U.S. state and local policy communications and external affairs | Previously handled regional field communications; has more than 12 years at the company. |
| Xcel Energy | Hanna Grene, global go-to-market and innovation leader for energy at Microsoft, has left to join the company | Will head its new Enterprise Growth and Commercialization group, effective Nov. 16. |
| LogicGate | Steve Smith, managing director of Europe, the Middle East and Africa, and Amanda Meglemre, general counsel | Join the enterprise software business, headquartered in Chicago with several C-suite executives working from Bellevue, Wash. |
| Kaiser Permanente | Ben Helsel, VP and general manager of commercial markets in Washington | Joins after leaving Premera Blue Cross. |
In energy technology, Avalanche Energy has appointed Chris Riegel, head of talent acquisition. He arrives from HiringKit, an HR company he co-founded, and previously worked at Amazon and Unity Technologies. The Seattle startup is developing fusion devices, leading a team working on DARPA’s nuclear battery challenge, and launching FusionWERX in Eastern Washington as a commercial-scale facility for testing fusion technologies.
Research and institutional support also feature in the changes. Julie Averill, former chief information officer at lululemon and REI, has joined the UW Foundation Board, which supports university fundraising. Jen Oleson, a senior director at Seattle-based consulting firm Slalom, has been appointed to the Technology Alliance board and will participate in its Research Capacity Committee.
What Businesses Can Take From the Appointments
The AI-focused moves identify distinct kinds of deployment work. Microsoft is building an enterprise agent platform, BECU is assigning internal transformation leadership, and Known is addressing accountability. Lila Bio and RevealDx are building development, medical and sales experience around specific healthcare applications, rather than general-purpose AI. Businesses assessing these developments can use the investment in leadership to understand priorities, but it doesn’t prove product performance. A practical next step is to look at the proposed workflow, establish who owns implementation and ask what results can be demonstrated. As AI moves closer to operational and clinical use, these appointments offer a view of where organizations are assigning responsibility.
